I nterstitial lung abnormalities are defined as specific patterns of increased lung density noted on chest computed tomography (CT) scans identified in participants with no prior history of interstitial lung disease. In studies of adults, interstitial lung abnormalities are present in approximately 2% to 10% of research participants [1] [2] [3] [4] [5] [6] [7] (and 7% of a general population sample) 6 and are associated with reductions in lung capacity, 1, 2, 6 exercise capacity, 8 gas exchange, 5, 6 and genetic abnormalities 6, 9 common to patients with familial interstitial pneumonia and idiopathic pulmonary fibrosis (IPF). 10 These data suggest that interstitial lung abnormalities may, in some cases, represent an early and/or mild form of pulmonary fibrosis. While radiologic abnormalities, worsening pulmonary function, and decreased exercise tolerance are important diagnostic features of IPF 11 (the most common and severe form of pulmonary fibrosis), 12 IPF is also associated with a high mortality rate. 13, 14 Although the survival rate of people with IPF appears to have increased slightly in recent years, 14 median survival time after diagnosis is 3 to 5 years, 13, 14 which is worse than that of most malignancies. 15 Given the other correlations between IPF and interstitial lung abnormalities, we hypothesized that the presence of interstitial lung abnormalities would be associated with an increased rate of mortality.
Methods

Study Design and Mortality Ascertainment
Protocols for participant enrollment and phenotyping in the FHS (Framingham Heart Study), the AGES-Reykjavik Study (Age Gene/Environment Susceptibility), the COPDGene Study (Genetic Epidemiology of COPD), and the ECLIPSE study (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) have been described previously. 2, 6, 16, 17 In all cohorts, race was self-reported based on fixed categories. Analyses were adjusted for race, given the known influence of race on mortality in other pulmonary diseases. In all cohorts, mortality refers to all-cause mortality unless otherwise indicated. Written informed consent was obtained from all participants. The institutional review boards of the Brigham and Women's Hospital and individual participating centers approved this study. The FHS is a longitudinal study originally designed to identify risk factors for cardiovascular disease in the general population. 18 The AGES-Reykjavik study is a longitudinal birth cohort from the Reykjavik Study (established in 1967) that now includes men and women born in Reykjavik, Iceland, between 1907 and 1935 who are monitored by the Icelandic Heart Association. The COPDGene study is a multicenter longitudinal study designed to identify the epidemiologic and genetic risk factors for chronic obstructive pulmonary disease (COPD). Participants with known active lung diseases other than asthma, emphysema, or COPD were excluded. 19 
Chest CT Analysis
The methods for chest CT characterization for interstitial lung abnormalities in the FHS and COPDGene cohorts 2, 6 were used to characterize interstitial lung abnormalities in AGESReykjavik and ECLIPSE (eMethods in the Supplement). In all cohorts, the chest CT scans were evaluated by as many as 3 readers (2 chest radiologists and 1 pulmonologist) using a sequential reading method. 22 Interstitial lung abnormalities were defined as nondependent changes affecting more than 5% of any lung zone, including reticular or ground-glass abnormalities, diffuse centrilobular nodularity, nonemphysematous cysts, honeycombing, or traction bronchiectasis (eFigure 1 in the Supplement). Chest CT images with focal or unilateral ground-glass attenuation, focal or unilateral reticulation, or patchy ground-glass abnormalities (<5% of any lung zone) were considered indeterminate (eFigure 2 in the Supplement). To explore the association between undiagnosed pulmonary fibrosis and mortality, an additional subset of interstitial lung abnormalities with pulmonary parenchymal architectural distortion diagnostic of fibrotic lung disease (definite fibrosis; Figure 1 ) was created. 6 Quantitative total lung volume and emphysema (percentage < −950 Hounsfield units [HU] ), where reported, were measured with Airway Inspector. 23 Coronary artery calcium scores were calculated using the traditional Agatston scoring method.
24
Statistical Analyses
In all cohorts except the FHS, association analyses between pairs of variables were conducted using Fisher exact tests for categorical variables and 2-tailed t tests for continuous variables. In the FHS, all analyses accounted for familial relationships using generalized estimating equations. 25 To evaluate the association between interstitial lung abnormalities and mortality, logistic regression was used to analyze rates of absolute mortality and Cox proportional hazards models were used to analyze time to mortality, with robust standard errors to account for familial correlation in FHS. In Cox models, all variables were assessed and none violated the proportional hazards assumption. Multivariable models included adjustments for age, race, sex, body mass index, pack-years of smoking, smoking status (current vs former), and GOLD stage (if available). Additional covariates were measures of coronary artery disease (CAD [self-report of CAD or adjudicated in the FHS and also of coronary artery calcium scores]) and history of self-reported nondermatologic malignancy. In the COPD cohorts, additional analyses were implemented using the BODE index (body mass index, air flow obstruction, dyspnea, and exercise) 26 as an alternative measure of COPD severity.
All P values were 2-sided and a level of .05 was considered 
ECLIPSE
Chest computed tomographic (CT) axial images of 4 participants, one from each cohort, with interstitial lung abnormalities with definite fibrosis. Definite fibrosis is defined as pulmonary parenchymal architectural distortion diagnostic of fibrotic lung disease. 
Results
Of 
Interstitial Lung Abnormality Prevalence
The prevalence of participants with interstitial lung abnormalities, without interstitial lung abnormalities, and with indeterminate interstitial lung abnormality status in the FHS 6 Figure 2 ). In the AGES-Reykjavik cohort, interstitial lung abnormalities were present in 378 (7%), were not present in 3216 (61%), and were indeterminate in 1726 (32%) ( Table 1 ; Figure 2 ). In ECLIPSE, interstitial lung abnormalities were present in 157 (9%), were not present in 528 (32%), and were indeterminate in 985 (59%) ( Table 1 ; Figure 2 ). Additional results about reading methodology are included in eResults (in the Supplement).
Baseline Characteristics and Interstitial Lung Abnormalities
The baseline characteristics of the participants from all 4 cohorts, stratified by the presence or absence of interstitial lung abnormalities, are presented in Table 1 . Baseline characteristics of AGES-Reykjavik and ECLIPSE participants, including those who were indeterminate for interstitial lung abnormalities, are included in eTable 1 and eTable 2 (in the Supplement). Across all cohorts, interstitial lung abnormalities were associated with older age when compared with the absence of interstitial lung abnormalities. As noted in the COPDGene study, 2 among participants in ECLIPSE, 23 interstitial lung abnormalities (when compared with absence of interstitial lung abnormalities) were associated with less-severe airway obstruction, as demonstrated by a higher forced expiratory volume in the first second (FEV 1 ) and FEV 1 /forced vital capacity (FVC) ratio. In contrast, in the FHS, interstitial lung abnormalities were associated with a higher prevalence of COPD and a lower FEV 1 /FVC ratio.
Mortality and Interstitial Lung Abnormalities
For all cohorts except the COPDGene Study, the absolute mortality rates were significantly higher among participants with interstitial lung abnormalities when compared with those who did not have interstitial lung abnormalities ( (Figure 3) . Similar results were seen, with higher odds of death, when using multivariable logistic regression (eTable 3 in the Supplement). For further analyses regarding definite fibrosis and participants who were indeterminate for interstitial lung abnormalities see eTable 5, eTable 6, and eFigure 3 in the Supplement.
Mortality, Interstitial Lung Abnormalities, and Never Smokers
To determine if unmeasured differences in smoking behavior among smokers could explain the associations between interstitial lung abnormalities and mortality, associations between interstitial lung abnormalities and mortality in never .04
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80 (6) 18 (11) 230 (20) 38 (25) 241 (46) 76 ( 167 (14) 11 (7) 219 (41) 74 (47) Stage 4 99 (8) 5 (3) 68 (13) 7 (5) TLC, L, mean (SD) smokers from both the FHS and AGES-Reykjavik cohorts were analyzed. In the FHS, 6% of never smokers with interstitial lung abnormalities died compared with 0.3% of never smokers who did not have interstitial abnormalities, a difference of 5.7% (95% CI, 1%-12%) and an HR of 19.9 (95% CI, 5.1-78.1; P < .001). In AGES-Reykjavik, 52% of never smokers with interstitial lung abnormalities died compared with 31% of those who did not have interstitial lung abnormalities, a difference of 21%, (95% CI, 11%-31%) and an HR of 1.3 (95% CI, 1.1-1.4; P = .002).
Mortality, Interstitial Lung Abnormalities, COPD, CAD, and Cancer
To determine if the presence of other chronic diseases could explain the associations between interstitial lung abnormalities and mortality, analyses were performed in each cohort, additionally adjusting for the percentage of emphysematous lung, measures of CAD or reports of malignancy (where available). The association between interstitial lung abnormalities and mortality remained statistically significant after additional ad- justments for disease-specific measures (Table 2) , except in the FHS and COPDGene, in which additional adjustment for adjudicated or self-report of CAD and coronary artery calcium scores resulted in no association (Table 2) . Similar associations between interstitial lung abnormalities and mortality were seen in COPDGene and ECLIPSE studies when adjusting for BODE index (eResults in the Supplement). Additionally, the absolute mortality rates of each GOLD stage were consistently greater among participants with interstitial lung abnormalities compared with those who did not have interstitial lung abnormalities (eFigure 4 in the Supplement).
Mortality, Interstitial Lung Abnormalities, and Cause of Death
To determine the causes of death among participants with interstitial lung abnormalities, data from the AGES-Reykjavik cohort were assessed (where causes-of-death were available) from death certificates on an interim follow-up date (December 31, 2009, median follow-up time, 5.4 years). Participants with interstitial lung abnormalities in the AGES-Reykjavik cohort were more likely to die of a respiratory cause (13%) compared with those who did not have interstitial lung abnormalities (4%) or those with indeterminate status (6%; see Table 3 ). After adjusting for covariates (age, sex, race, BMI, pack-years of smoking, current smoking status), participants with interstitial lung abnormalities had a higher odds ratio (OR) of death from a respiratory cause (OR, 2.4 [95% CI, 1.7-3.4]; P < .001) compared with those who did not have interstitial lung abnormalities. Results were similar when comparing participants with interstitial lung abnormalities with those who were indeterminate for interstitial lung abnormalities (eResults in the Supplement). After adjusting for covariates, there was no association between interstitial lung disease status and death due to cardiovascular disease, cancer, or other causes. Among participants who died of a respiratory cause, interstitial lung abnormalities were associated with an increased rate of death from pulmonary fibrosis ([47%], 7 of the 15 respiratory deaths among those with interstitial lung abnormalities were from pulmonary fibrosis; Table 3 ). Of the 8 deaths due to pulmonary fibrosis, 5 participants had evidence of definite fibrosis on chest CT, 2 had interstitial lung abnormalities without definite fibrosis, and 1 participant was indeterminate for interstitial lung abnormality status. Only 1 of these participants had previously diagnosed pulmonary fibrosis at the time of the CT scan.
Discussion
In this study, interstitial lung abnormalities, a set of imaging abnormalities noted among approximately 7% of adult participants, 6 were associated with a higher rate of all-cause mortality. The associations between interstitial lung abnormalities and mortality were not attenuated after adjustment for smoking, cancer, COPD, or CAD. Among an older population from Iceland, the higher rate of mortality in those with interstitial lung abnormalities was associated with a higher rate of death from respiratory failure and pulmonary fibrosis. These findings, in conjunction with those previously published, 2, 6, 8 demonstrate that despite often being undiagnosed and asymptomatic, 2, 6 interstitial lung abnormalities may be associated with lower survival rates among older persons. This study builds on prior studies, 7 demonstrating that interstitial lung abnormalities were associated with older age, smoking, and a restrictive lung deficit. The findings in ECLIPSE are similar to those previously reported in COPDGene, 2 which demonstrated that among smokers with COPD, interstitial lung abnormalities were identified among those with more preserved FEV 1 /FVC ratios. Although COPD was associated with interstitial lung abnormalities in the FHS, this association may be related to older age and history of smoking, which are common in both COPD and interstitial lung abnormalities.
It is important to consider the higher mortality rates associated with interstitial lung abnormalities in context. The mortality rates associated with interstitial lung abnormalities are lower than the well-documented mortality rates associated with clinically identified IPF. 13, 14 In addition, although data from the AGES-Reykjavik cohort demonstrated that interstitial lung abnormalities were associated with death caused by respiratory failure and pulmonary fibrosis, respiratory failure death is more common in patients with IPF.
11,27
The absolute mortality rates differed between the cohorts. This was due, in part, to differences in recruitment criteria and follow-up time. Compared with the FHS (which included a general population sample of adults), the higher absolute mortality rates in COPDGene and ECLIPSE are likely explained by a longer follow-up time (COPDGene) and the inclusion of greater numbers of COPD patients (COPDGene and ECLIPSE). Although the FHS and AGES-Reykjavik participants were recruited from community-dwelling men and women, the higher mortality rates in the AGES-Reykjavik cohort are likely explained by the older age and longer follow-up times of the average participants in this cohort.
This study has some limitations. First, participants with interstitial lung abnormalities were older than those without interstitial lung abnormalities. 7 Therefore, residual confounding is possible even after adjustment. Second, further study is needed to determine the prognostic significance of interstitial lung abnormalities in younger age groups. Third, further studies are needed to identify imaging findings on CT scan that may simply reflect a normal variant of the aging lung 28 rather than an early stage of progressive interstitial lung disease. Fourth, interstitial lung abnormalities were associated with a higher risk of death among never smokers from 2 cohorts; however, the large hazard of mortality associated with interstitial lung abnormalities in the FHS among never smokers was driven by a small number of deaths. Fifth, although an association between interstitial lung abnormalities and increased risk of respiratory death was identified in the AGES-Reykjavik study, data regarding the cause of death were not available from other cohorts. Sixth, despite the correlations presented between research participants with interstitial lung abnormalities and patients with IPF (as well as other forms of interstitial lung disease), this study cannot explain the large discrepancy between the prevalence of interstitial lung abnormalities (7% in general population samples 6 ; Table 1 ) and the reported prevalence of IPF (≈ 0.002%-0.04% of the general population) 29-31 and interstitial lung disease. Of note, the prevalence of definite fibrosis in each cohort (≈ 1.6%-2.4%) is similar to the prevalence of IPF noted in an autopsy study of 510 cases from New Mexico (1.8%) even though IPF was suspected as a cause of death in less than one-tenth of these cases. 32 Seventh, unmeasured confounders could explain these findings. Eighth, there are differences in the estimates of the association of interstitial lung abnormalities on mortality in unadjusted and adjusted models in the FHS. Ninth, although data on interobserver variability in interstitial lung abnormality scoring are presented, data on intraobserver variability in interstitial lung abnormality scoring were not recorded. Follow-up studies should determine the risk factors for and the events that lead to death among persons with interstitial lung abnormalities. Given the ability to treat more advanced stages of pulmonary fibrosis, 33,34 future clinical trials attempting to reduce the overall mortality associated with pulmonary fibrosis should consider including early stages of the disease.
Conclusions
In 4 separate research cohorts, interstitial lung abnormalities were associated with a greater risk of all-cause mortality. The clinical implications of this association require further investigation.
